Company Overview of Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing R...
2020 Avon Court
Charlottesville, VA 22902
Key Executives for Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. does not have any Key Executives recorded.
Diffusion Pharmaceuticals Inc. Key Developments
Diffusion Pharmaceuticals Inc. Announces Earnings Results for the Year Ended December 31, 2016
Mar 31 17
Diffusion Pharmaceuticals Inc. announced earnings results for the year ended December 31, 2016. Net loss was $18.0 million for the year ended December 31, 2016, compared to a net loss of $6.7 million for the year ended December 31, 2015. The increase in the net loss was primarily due to higher expenses associated with research and development and general and administrative costs.
Diffusion Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
Mar 31 17
Diffusion Pharmaceuticals Inc. filed its 10-K on Mar 31, 2017 for the period ending Dec 31, 2016. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Diffusion Pharmaceuticals Inc. Announces Trans Sodium Crocetinate Phase 1/2 Glioblastoma Multiforme Clinical Trial Results
Feb 8 17
Diffusion Pharmaceuticals Inc. announced that the data from the Phase 1/2 clinical trial evaluating the safety and efficacy of trans sodium crocetinate (TSC) in newly diagnosed glioblastoma multiforme (GBM). Results from the Phase 1/2 clinical trial in 59 patients showed that 36.3% of the full TSC dose patients were alive at two years, compared to historical two-year survival rates ranging from 27% to 30%. TSC, the Company’s lead product candidate, is designed to target the tumor’s reduced oxygen microenvironment. TSC re-oxygenates cancerous tissue, thus making the cancer cells more susceptible to current radiation therapy and chemotherapy. The article, entitled, 'Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme,' outlines the results of a Phase 1/2 trial designed to evaluate the therapeutic effect of adding TSC to radiation therapy in 59 newly diagnosed GBM patients. In this trial, all patients received radiation with the drug temozolomide beginning either after surgery or biopsy of the tumor. TSC was administered around 45 minutes before each radiation session three days per week during the 6 weeks of radiation therapy. Considerable tumor shrinkage was seen in many patients, with tumors in 11 patients disappearing completely. Oxygen deprivation at the cellular level is the result of rapid tumor growth, causing the tumor to outgrow its blood supply. Cancerous tumor cells thrive with hypoxia and the resultant changes in the tumor microenvironment cause 'treatment-resistance' to radiation therapy and chemotherapy. Using a novel, proprietary mechanism of action, Diffusion’s lead drug TSC counteracts tumor hypoxia – and therefore treatment-resistance – by safely re-oxygenating tumor tissue, thus enhancing tumor kill and potentially prolonging patients’ life expectancy. Oxygen levels of normal tissue remain unaffected upon administration of TSC, thereby avoiding the introduction of harmful side effects.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 14, 2017
November 8, 2016